Skip to main contentSkip to main content
Updating results


  • Updated

Another major insulin maker has promised steep price cuts, as pressure grows on drugmakers and insurers to trim the cost of a medication that millions of Americans need. Novo Nordisk said Tuesday that it will slash some of its U.S. insulin prices up to 75% starting next year. The announcement comes less than two weeks after rival Eli Lilly said it will drop some of its prices by 70% or more later this year. Diabetes care experts say cuts on the initial prices drugmakers charge are only a step toward making insulin more widely affordable.

  • Updated

Eli Lilly will cut prices for some older insulins later this year and immediately give more patients access to a cap on the costs they pay to fill prescriptions. The moves promise critical relief to some people with diabetes who can face annual costs of more than $1,000 for insulin. Lilly’s changes also come as lawmakers pressure drugmakers to do something about soaring prices. Lilly said it will cut the list price for its most commonly prescribed insulin, Humalog, and for another insulin, Humulin, by 70% or more in the fourth quarter.

A new pill aims to make it easier to treat diabetic cats without insulin shots twice a day. The drug is the first oral treatment for feline diabetes approved by the Food and Drug Administration. 

Get up-to-the-minute news sent straight to your device.


News Alerts

Breaking News